Novonesis Human Health Sales Fall 8%
The decline reflects weaker North American dietary supplement demand, which the company expects to recover only in the second half of 2027.
Updated on Nov. 5, 2026 in Nutrition
Live Poll
Have you cut back on buying vitamins or dietary supplements recently?
Novonesis reported that its Human Health business revenue fell 8% in the third quarter, as declines in North American offline dietary supplement sales offset growth elsewhere. The company's group revenue still grew 6% organically.
Why it matters
Novonesis CEO Ester Baiget said changing US consumer behaviour and weaker buying power are weighing on the North American dietary supplement market. European peer dsm-firmenich also flagged cautious consumer behaviour in North America in its results released earlier this week.
Novonesis reported an 8% revenue decline in its Human Health business in the third quarter, against 6% organic group growth and 14% growth in its Food & Beverages division. The company expects North American dietary supplement demand to return to growth only in the second half of 2027, and the extraction does not detail how that projection may change.
The players
Novonesis
A Danish biotechnology company that supplies enzymes, microorganisms and ingredients to food, health and industrial markets.
Ester Baiget
The chief executive of Novonesis who has led the company's public communication on its Human Health results and market outlook.
dsm-firmenich
A Dutch-Swiss nutrition, health and beauty ingredients company that reports results alongside Novonesis and competes in similar markets.
The details
Human Health revenue fell in the quarter because offline dietary supplement sales in North America declined, a drop that outweighed growth in supplements in other regions. CEO Ester Baiget addressed the market weakness on a post-earnings call and in a statement issued Thursday.
Timeline
Third quarter of 2026: Human Health revenue fell 8%.
Earlier in the week of November 2, 2026: dsm-firmenich flagged cautious North American consumer behaviour.
Thursday, November 5, 2026: Novonesis CEO commented on the market weakness.
Second half of 2027: Expected return to growth in North American dietary supplements.
Nutrition Outlook
Novonesis's Human Health slump mirrors the cautious North American consumer pattern dsm-firmenich reported in the same week, suggesting the weakness is shared across major supplement ingredient suppliers rather than unique to one company. The expected return to growth in the second half of 2027 places the downturn within a multi-quarter recovery window.
Shoppers buying dietary supplements in North America may see softer offline demand and shifting product availability as the category slows through 2027. The slowdown reflects weaker buying power, so households managing supplement budgets may find more room to delay or cut back purchases.
The takeaway
Consumer spending on dietary supplements is tightening, so reviewing which products you truly need can help stretch a budget during a slower market. Watch for the expected return to growth before assuming the category has recovered.
What happens next
Novonesis expects the North American dietary supplement market to return to growth in the second half of 2027.
Further reading
For broader context on how supplement demand is shifting, see our Nutrition coverage.
Live Poll
Have you cut back on buying vitamins or dietary supplements recently?
